Pnc Financial Services Group, Inc. Intellia Therapeutics, Inc. Transaction History

Pnc Financial Services Group, Inc.

$156 Billion
Q3 2024

A detailed history of Pnc Financial Services Group, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 16,860 shares of NTLA stock, worth $241,098. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,860

Previous 16,324 3.28%

Holding current value

$241,098

Previous $365,000 5.21%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$19.72 - $27.36 $10,569 - $14,664	536 Added 3.28%	16,860 $346,000
Q2 2024 Aug 09, 2024	BUY	$20.02 - $27.22 $7,367 - $10,016	368 Added 2.31%	16,324 $365,000
Q1 2024 May 10, 2024	BUY	$23.82 - $32.8 $128,508 - $176,955	5,395 Added 51.08%	15,956 $438,000
Q4 2023 Feb 09, 2024	BUY	$23.16 - $32.34 $165,617 - $231,263	7,151 Added 209.71%	10,561 $322,000
Q3 2023 Nov 13, 2023	SELL	$31.62 - $45.78 $11,288 - $16,343	-357 Reduced 9.48%	3,410 $107,000
Q2 2023 Aug 11, 2023	BUY	$34.58 - $46.03 $8,990 - $11,967	260 Added 7.41%	3,767 $153,000
Q1 2023 May 15, 2023	SELL	$33.3 - $44.82 $832 - $1,120	-25 Reduced 0.71%	3,507 $130,000
Q4 2022 Feb 10, 2023	BUY	$33.21 - $62.69 $1,162 - $2,194	35 Added 1.0%	3,532 $123,000
Q3 2022 Nov 10, 2022	SELL	$53.92 - $71.7 $916 - $1,218	-17 Reduced 0.48%	3,497 $195,000
Q2 2022 Aug 12, 2022	SELL	$38.49 - $76.21 $155,615 - $308,117	-4,043 Reduced 53.5%	3,514 $181,000
Q1 2022 May 12, 2022	SELL	$58.27 - $118.99 $392,739 - $801,992	-6,740 Reduced 47.14%	7,557 $549,000
Q4 2021 Feb 11, 2022	SELL	$100.76 - $138.36 $353,969 - $486,058	-3,513 Reduced 19.72%	14,297 $1.69 Million
Q3 2021 Nov 05, 2021	SELL	$132.37 - $176.78 $103,513 - $138,241	-782 Reduced 4.21%	17,810 $2.39 Million
Q2 2021 Aug 06, 2021	BUY	$60.88 - $161.91 $2,191 - $5,828	36 Added 0.19%	18,592 $3.01 Million
Q1 2021 May 07, 2021	BUY	$46.59 - $83.68 $9,224 - $16,568	198 Added 1.08%	18,556 $1.49 Million
Q4 2020 Feb 12, 2021	BUY	$18.83 - $63.53 $94,149 - $317,650	5,000 Added 37.43%	18,358 $998,000
Q3 2020 Nov 06, 2020	BUY	$17.47 - $24.93 $11,495 - $16,403	658 Added 5.18%	13,358 $265,000
Q2 2020 Aug 07, 2020	SELL	$11.14 - $22.87 $111,400 - $228,700	-10,000 Reduced 44.05%	12,700 $266,000
Q1 2020 May 08, 2020	BUY	$9.44 - $15.58 $25,488 - $42,066	2,700 Added 13.5%	22,700 $277,000
Q4 2019 Feb 07, 2020	BUY	$10.43 - $17.67 $114,208 - $193,486	10,950 Added 120.99%	20,000 $293,000
Q3 2019 Nov 08, 2019	SELL	$13.07 - $18.51 $12,416 - $17,584	-950 Reduced 9.5%	9,050 $120,000
Q2 2019 Aug 09, 2019	SELL	$13.88 - $18.41 $6,731 - $8,928	-485 Reduced 4.63%	10,000 $0
Q1 2019 May 10, 2019	BUY	$12.79 - $17.62 $6,203 - $8,545	485 Added 4.85%	10,485 $0
Q4 2018 Feb 08, 2019	BUY	$11.39 - $27.13 $113,900 - $271,300	10,000 New	10,000 $136,000
Q4 2017 Feb 09, 2018	SELL	$17.39 - $31.12 $1,739 - $3,112	-100 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$15.16 - $25.75 $1,516 - $2,575	100	100 $0

Others Institutions Holding NTLA

# of Institutions

313

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.09B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.

Account

Pnc Financial Services Group, Inc. Intellia Therapeutics, Inc. Transaction History